Combined determination of serum CA 19–9 and tissue polypeptide antigen

Why no improvement in pancreatic cancer diagnosis?

D. Basso, C. Fabris, G. del Favero, A. Panucci, M. Plebani, C. Angonese, G. Leandro, G. Dodi, A. Burlina, Remo Naccarato

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CA 19-9 and tissue polypeptide antigen (TPA) were determined in the sera of 28 control subjects. 29 patients with pancreatic cancer, 26 with chronic pancreatitis and 62 with benign and malignant extra pancreatic diseases in order to compare their usefulness in diagnosing pancreatic cancer, to verify whether the combined assessment of the two indices could improve the results given by a single parameter and to speculate on the role of liver dysfunction in increasing their serum levels. The sensitivity, specificity and accuracy of CA 19-9 and TPA in diagnosing pancreatic malignancy were: 76. 85 and 61% for CA 19-9 and 79. 52 and 32% lor TPA. The receiver-operating characteristic curves showed that CA 19-9 and TPA similarly discriminate pancreatic cancer from controls and chronic pancreatitis, while CA 19-9 is more useful than TPA in differentiat- ing pancreatic malignancy from benign and malignant extra pancreatic abdominal diseases. TPA did not seem to add further information as compared to CA 19-9 alone when both markers were combined. Liver dysfunction may contribute to increasing serum levels of both markers.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalOncology
Volume45
Issue number1
DOIs
Publication statusPublished - 1988

Fingerprint

Tissue Polypeptide Antigen
Pancreatic Neoplasms
Serum
Pancreatic Diseases
Chronic Pancreatitis
Liver Diseases
ROC Curve
Neoplasms
Sensitivity and Specificity

Keywords

  • CA 19-9
  • Pancreatic cancer
  • Tissue polypeptide antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Basso, D., Fabris, C., del Favero, G., Panucci, A., Plebani, M., Angonese, C., ... Naccarato, R. (1988). Combined determination of serum CA 19–9 and tissue polypeptide antigen: Why no improvement in pancreatic cancer diagnosis? Oncology, 45(1), 24-29. https://doi.org/10.1159/000226525

Combined determination of serum CA 19–9 and tissue polypeptide antigen : Why no improvement in pancreatic cancer diagnosis? / Basso, D.; Fabris, C.; del Favero, G.; Panucci, A.; Plebani, M.; Angonese, C.; Leandro, G.; Dodi, G.; Burlina, A.; Naccarato, Remo.

In: Oncology, Vol. 45, No. 1, 1988, p. 24-29.

Research output: Contribution to journalArticle

Basso, D, Fabris, C, del Favero, G, Panucci, A, Plebani, M, Angonese, C, Leandro, G, Dodi, G, Burlina, A & Naccarato, R 1988, 'Combined determination of serum CA 19–9 and tissue polypeptide antigen: Why no improvement in pancreatic cancer diagnosis?', Oncology, vol. 45, no. 1, pp. 24-29. https://doi.org/10.1159/000226525
Basso, D. ; Fabris, C. ; del Favero, G. ; Panucci, A. ; Plebani, M. ; Angonese, C. ; Leandro, G. ; Dodi, G. ; Burlina, A. ; Naccarato, Remo. / Combined determination of serum CA 19–9 and tissue polypeptide antigen : Why no improvement in pancreatic cancer diagnosis?. In: Oncology. 1988 ; Vol. 45, No. 1. pp. 24-29.
@article{4c6c1a35b42c4e8591c8044a88d09407,
title = "Combined determination of serum CA 19–9 and tissue polypeptide antigen: Why no improvement in pancreatic cancer diagnosis?",
abstract = "CA 19-9 and tissue polypeptide antigen (TPA) were determined in the sera of 28 control subjects. 29 patients with pancreatic cancer, 26 with chronic pancreatitis and 62 with benign and malignant extra pancreatic diseases in order to compare their usefulness in diagnosing pancreatic cancer, to verify whether the combined assessment of the two indices could improve the results given by a single parameter and to speculate on the role of liver dysfunction in increasing their serum levels. The sensitivity, specificity and accuracy of CA 19-9 and TPA in diagnosing pancreatic malignancy were: 76. 85 and 61{\%} for CA 19-9 and 79. 52 and 32{\%} lor TPA. The receiver-operating characteristic curves showed that CA 19-9 and TPA similarly discriminate pancreatic cancer from controls and chronic pancreatitis, while CA 19-9 is more useful than TPA in differentiat- ing pancreatic malignancy from benign and malignant extra pancreatic abdominal diseases. TPA did not seem to add further information as compared to CA 19-9 alone when both markers were combined. Liver dysfunction may contribute to increasing serum levels of both markers.",
keywords = "CA 19-9, Pancreatic cancer, Tissue polypeptide antigen",
author = "D. Basso and C. Fabris and {del Favero}, G. and A. Panucci and M. Plebani and C. Angonese and G. Leandro and G. Dodi and A. Burlina and Remo Naccarato",
year = "1988",
doi = "10.1159/000226525",
language = "English",
volume = "45",
pages = "24--29",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Combined determination of serum CA 19–9 and tissue polypeptide antigen

T2 - Why no improvement in pancreatic cancer diagnosis?

AU - Basso, D.

AU - Fabris, C.

AU - del Favero, G.

AU - Panucci, A.

AU - Plebani, M.

AU - Angonese, C.

AU - Leandro, G.

AU - Dodi, G.

AU - Burlina, A.

AU - Naccarato, Remo

PY - 1988

Y1 - 1988

N2 - CA 19-9 and tissue polypeptide antigen (TPA) were determined in the sera of 28 control subjects. 29 patients with pancreatic cancer, 26 with chronic pancreatitis and 62 with benign and malignant extra pancreatic diseases in order to compare their usefulness in diagnosing pancreatic cancer, to verify whether the combined assessment of the two indices could improve the results given by a single parameter and to speculate on the role of liver dysfunction in increasing their serum levels. The sensitivity, specificity and accuracy of CA 19-9 and TPA in diagnosing pancreatic malignancy were: 76. 85 and 61% for CA 19-9 and 79. 52 and 32% lor TPA. The receiver-operating characteristic curves showed that CA 19-9 and TPA similarly discriminate pancreatic cancer from controls and chronic pancreatitis, while CA 19-9 is more useful than TPA in differentiat- ing pancreatic malignancy from benign and malignant extra pancreatic abdominal diseases. TPA did not seem to add further information as compared to CA 19-9 alone when both markers were combined. Liver dysfunction may contribute to increasing serum levels of both markers.

AB - CA 19-9 and tissue polypeptide antigen (TPA) were determined in the sera of 28 control subjects. 29 patients with pancreatic cancer, 26 with chronic pancreatitis and 62 with benign and malignant extra pancreatic diseases in order to compare their usefulness in diagnosing pancreatic cancer, to verify whether the combined assessment of the two indices could improve the results given by a single parameter and to speculate on the role of liver dysfunction in increasing their serum levels. The sensitivity, specificity and accuracy of CA 19-9 and TPA in diagnosing pancreatic malignancy were: 76. 85 and 61% for CA 19-9 and 79. 52 and 32% lor TPA. The receiver-operating characteristic curves showed that CA 19-9 and TPA similarly discriminate pancreatic cancer from controls and chronic pancreatitis, while CA 19-9 is more useful than TPA in differentiat- ing pancreatic malignancy from benign and malignant extra pancreatic abdominal diseases. TPA did not seem to add further information as compared to CA 19-9 alone when both markers were combined. Liver dysfunction may contribute to increasing serum levels of both markers.

KW - CA 19-9

KW - Pancreatic cancer

KW - Tissue polypeptide antigen

UR - http://www.scopus.com/inward/record.url?scp=0023870420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023870420&partnerID=8YFLogxK

U2 - 10.1159/000226525

DO - 10.1159/000226525

M3 - Article

VL - 45

SP - 24

EP - 29

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 1

ER -